The GLP-1 and Cagrilintide Blend is an advanced, high-purity dual compound designed for metabolic and appetite regulation research. This 5mg/5mg formulation merges two scientifically significant peptides to support the study of energy balance, body composition, and glycemic control through a complementary, multi-pathway approach.

GLP-1 (glucagon-like peptide-1) is a long-acting receptor agonist that simulates the activity of the body’s natural GLP-1 hormone. It has been extensively studied for its role in reducing appetite, delaying gastric emptying, and regulating blood glucose levels—critical elements in metabolic health. Its prolonged half-life enhances its stability and reliability in extended research models.

Cagrilintide is a synthetic analogue of amylin, a hormone secreted alongside insulin. It plays a vital role in promoting post-meal satiety, moderating glucose spikes, and enhancing the sensation of fullness. Unlike GLP-1, it targets amylin receptors, allowing for complementary metabolic effects without receptor overlap.

When used in combination, these peptides create a dual-action framework for investigating enhanced outcomes in weight regulation, appetite suppression, insulin sensitivity, and neuroendocrine control of food intake. The synergistic nature of GLP-1 and Cagrilintide positions this blend as a forefront option in metabolic peptide research.

Use with bacteriostatic water